Brief: Grand Pharmaceutical Says NMPA Accepts Application For Group's RDC TLX591
07/05/2025 12:27
May 7 (Reuters) - Grand Pharmaceutical Group Ltd 0512.HK: GRAND PHARMACEUTICAL - APPLICATION FOR GROUP'S RDC TLX591 TO JOIN INTERNATIONAL MULTICENTER PHASE III CLINICAL TRIAL IS ACCEPTED BY NMPA Further company coverage: 0512.HK ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Grand Pharmaceutical
See all newsBrief: Grand Pharmaceutical Group Declares No Interim Dividend Has Been Paid
Grand Pharmaceutical H1 revenue rises on nuclear medicine demand
Grand Pharma rises most in over a year as drug gets US FDA fast track designation
GPN01530-2 Granted Fast Track Designation By FDA
Brief: Grand Pharmaceutical Group Enters Huadong Medicine Supply Agreement